about
Automated Blood Cell CountsEffect of maternal smoking on breast milk interleukin-1alpha, beta-endorphin, and leptin concentrations and leptin concentrations.Expression analysis and prognostic significance of human kallikrein 11 in prostate cancerSerum YKL-40 following resection for cerebral glioblastomaAccreditation of medical laboratories in the European UnionMeat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC)Reference intervals for hemoglobin A1c in pregnant women: data from an Italian multicenter study.Managing transferability of laboratory data.Maldi-TOF analysis of portal sera of pancreatic cancer patients: identification of diabetogenic and antidiabetogenic peptides.A real-world evidence-based approach to laboratory reorganization using e-Valuate benchmarking data.An approach for estimating measurement uncertainty in medical laboratories using data from long-term quality control and external quality assessment schemes.Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide.Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.Pancreatic cancer alters human CD4+ T lymphocyte function: a piece in the immune evasion puzzle.Platelet response to Helicobacter pylori eradication therapy in adult chronic idiopathic thrombocytopenic purpura seems to be related to the presence of anticytotoxin-associated gene A antibodies.Presence of anti-ADAMTS13 antibodies in obesity.Defective ADAMTS13 synthesis as a possible consequence of NASH in an obese patient with recurrent thrombotic thrombocytopenic purpura.Spondyloarthritis: Matrix Metalloproteinasesas Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors.SerpinB3 Promotes Pro-fibrogenic Responses in Activated Hepatic Stellate Cells.Patient and Sample Identification. Out of the Maze?Quality Indicators in Laboratory Medicine: from theory to practice. Preliminary data from the IFCC Working Group Project "Laboratory Errors and Patient Safety".Errors in laboratory medicine.State of the art of BNP and NT-proBNP immunoassays: the CardioOrmoCheck study.Usefulness of MALDI-TOF/MS identification of low-MW fragments in sera for the differential diagnosis of pancreatic cancer.Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study.Clinical significance of cytokine determination in synovial fluid.Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis.Esophageal cancer management: preoperative CA19.9 and CEA serum levels may identify occult advanced adenocarcinoma.Inflammation and pancreatic cancer: molecular and functional interactions between S100A8, S100A9, NT-S100A8 and TGFβ1Appropriateness in programs for continuous quality improvement in clinical laboratories.Interpretative comments and reference ranges in EQA programs as a tool for improving laboratory appropriateness and effectiveness.Appropriateness of cholesterol and triglycerides reporting checked by External Quality Assessment programs.Clinical value and measurement of specific IgE.TNFA Haplotype Genetic Testing Improves HLA in Estimating the Risk of Celiac Disease in Children.Clinical utility of the (-2)proPSA and evaluation of the evidence: a systematic review.Performance specifications of critical results management.Calcitonin measurement and immunoassay interference: a case report and literature review.Extra-analytical quality indicators and laboratory performances.Reporting altered test results in hemolyzed samples: is the cure worse than the disease?Performance specifications for the extra-analytical phases of laboratory testing: Why and how.
P50
Q22306117-5390F8C5-E9FD-47D6-B423-0A193B6DBFDBQ24816191-F64A706B-82F6-49E4-8F9A-EB826657ADD7Q28250722-D89527B1-E52A-45C4-B33F-A484818EE609Q28253544-F5FCEA92-2421-4D99-9A45-C14CD43EFF16Q28289147-4227FF1E-D38D-4023-B8BE-0A8091C21AD4Q28299632-533FDBE4-88EB-4C97-913D-500FEAF4674AQ31036283-088C37BA-A659-4CF5-AFC0-BEE917597D27Q31049507-3EBC3937-7907-4E7E-A783-AC2FE7BF1F18Q31054028-6C5E1C42-5662-4A46-9FD5-9BB9CB6571BAQ31132500-3F9AA19D-2A84-4655-AB1E-B41829AEFC97Q31168021-628C957D-CB8F-46FD-A912-FE556115D240Q32047496-2C365A86-B74E-45A2-AA68-7970776752B1Q33350682-126A912D-6F20-439D-B757-DFE7CD679B92Q33351879-ABF15B38-D257-460A-B298-2A645151A66BQ33386409-F13F6A03-518D-4384-A3D9-B37B50520B64Q33403187-A9A37EEB-9700-415D-A37A-F74F1A2594BFQ33412873-8A7BC0DC-ED6F-4FA8-AD23-F9CA2E5B6205Q33624763-36736900-41E8-4D1C-BD1C-7A9BFCB815E8Q33794042-1DE7FBA4-15E9-4538-BA2E-8454FCF9F3CAQ33801044-5AD6DDFC-7F92-4933-876C-D43E84FE0C09Q33826728-146EFA05-791A-4661-9B40-C32CC28D7533Q34125689-A5857511-08E2-43FD-86C1-91F2A75AC0C3Q34295200-45D2EC27-FAEB-4841-96E1-D53C5DFC04C8Q34524303-8A7598C7-4E1C-4132-B034-9EE980C4BE51Q34546250-0A340D13-A9A9-4213-8FEF-FCE624A8A363Q34559795-C5FB0E56-4312-4AD7-B3EE-B0794B0EAA79Q34615283-378E1889-AE62-45CF-AEBE-5519C1E9D3FAQ34665749-C86E48CB-D8FF-4BA3-800C-D41C7724A7C6Q35131817-750F52A9-2EC0-4E3A-8967-31A8E39AE461Q35172656-5E9D7CBD-5102-47B4-9C41-FB32DE4BF404Q35172670-AB14C730-2DF0-45E3-8790-F9F8E4D5281EQ35172672-7399DE00-4717-49E9-B1C0-500A21FCDA54Q35209859-12762E11-93D0-4490-8D34-1E43BEEA966CQ35542563-164DCAB7-6B26-45C2-8B22-45FD847F2581Q38648521-EB945519-E44E-4C58-A4EB-DCB2EC81EB1FQ38677962-5F3C6F00-0B31-4D47-9EC8-5FF900818B3BQ38831701-22547348-AF8E-4C94-9480-94EECEDCA3F9Q38873109-7A155AC6-C1C7-49A5-A4A6-58E1CF4F51C8Q38957655-307A2A9C-68BA-4A16-A839-932E64C56060Q38975704-8F3EBBF1-E0EC-4DB6-BA82-9D860B8AD356
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mario Plebani
@ast
Mario Plebani
@bar
Mario Plebani
@de
Mario Plebani
@en
Mario Plebani
@es
Mario Plebani
@fr
Mario Plebani
@it
Mario Plebani
@nl
Mario Plebani
@sl
type
label
Mario Plebani
@ast
Mario Plebani
@bar
Mario Plebani
@de
Mario Plebani
@en
Mario Plebani
@es
Mario Plebani
@fr
Mario Plebani
@it
Mario Plebani
@nl
Mario Plebani
@sl
prefLabel
Mario Plebani
@ast
Mario Plebani
@bar
Mario Plebani
@de
Mario Plebani
@en
Mario Plebani
@es
Mario Plebani
@fr
Mario Plebani
@it
Mario Plebani
@nl
Mario Plebani
@sl
P106
P21
P31
P496
0000-0002-0270-1711
P5008
P569
2000-01-01T00:00:00Z